iNtRON Biotechnology, Inc (048530) Fair Value & Analysis
Healthcare · KR · Market cap 80.9B KRW
Fair value as of: Jul 6, 2026
From 1 valuation models · updated today
Fair value updated Jul 6, 2026 — revised from 10,178 KRW to 1,274 KRW (−87.5%) since Jun 24, 2026. Share price −10.9% over the past month.
Price vs Fair Value (12 months)
12‑month range 2,365 KRW – 6,650 KRW · fair‑value band 841.06 KRW – 1,593 KRW · the 2,420 KRW price screens above the 1,274 KRW fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
iNtRON Biotechnology, Inc (048530) currently trades at 2,420 KRW, while our model-based Fair Value estimate is 1,274 KRW — implying the stock looks roughly 47.3% overvalued today. We read business quality at 37/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 5.7B KRW. Revenue grew 12.0% year over year. It earns a return on equity of -11.7%. Fundamentals as of Jul 6, 2026
Our scenario range runs from 841.06 KRW (bear case) to 1,593 KRW (bull case); at 2,420 KRW, the current price sits above that range. The share trades about 65% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside — at -47%, 048530 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
iNtRON Biotechnology, Inc. engages in the development of novel biopharmaceutical drugs in South Korea. It develops bacteriophage and endolysin based drugs through itLysin and IMPA platform. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
iNtRON Biotechnology, Inc reported revenue of 5.7B KRW in FY2025 versus 29.3B KRW in FY2021, a compound −33.5%/yr. Reported net income was −9.0B KRW in FY2025.
Is 048530 fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $612.50 | $1,280 | +109% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
| CSL Limited CSL | A$116.32 | A$126.60 | +9% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| Moderna, Inc M1RN34 | R$12.44 | R$5.11 | -59% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is iNtRON Biotechnology, Inc (048530) undervalued?
What is the fair value of 048530?
What is the quality score of 048530?
What is the revenue of iNtRON Biotechnology, Inc (048530)?
What is the net profit margin of 048530?
Does iNtRON Biotechnology, Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.